BeOne Medicines (ONC) investor relations material

Strategic approach and infrastructure

• Built a unique global infrastructure with 6,000 staff, enabling rapid, cost-effective clinical trials in 40-50 countries.

• Focuses on in-house manufacturing and R&D, avoiding reliance on third parties for speed and data quality.

• Introduced 16 new molecular entities into the clinic in the past two years, with plans to increase this pace.

• Maintains a broad pipeline across small molecules, degraders, ADCs, and biologics, with particular strength in protein degradation.

• Leverages the BeOne Global Superhighway for efficient research, development, and triage of impactful medicines.

Financial and geographic performance

• Achieved profitability and strong financial performance, with $125 million net income and $354 million free cash flow in Q3.

• Over 50% of revenue comes from the U.S., with rapid growth in Europe (71% YoY) and rest of world (133% YoY).

• Significant manufacturing investments, including an $800 million biologics facility in New Jersey.

• Business profile is evolving to resemble a mature global biopharmaceutical company.

CLL franchise and clinical strategy

• CLL vision is to provide optimal treatment for all patient subtypes and stages, with three key medicines: BRUKINSA (BTK inhibitor), BCL2 inhibitor, and BTK degrader.

• BRUKINSA shows superior PFS and OS data, outperforming other BTK inhibitors in head-to-head trials.

• BCL2 inhibitor demonstrates faster, deeper MRD negativity than existing combinations, effective in both mutated and unmutated populations.

• BTK degrader offers broader applicability for resistant mutations, with head-to-head trials against pirtobrutinib underway.

• Phase III head-to-head trials are prioritized to establish clear clinical superiority and market leadership.